With billions of dollars now directed toward its development, radioligand therapy has the potential to transform cancer treatment. The excitement is driving cancer centers nationwide to expand theranostic trials which pair RLT with novel radiopharmaceutical PET or SPECT imaging. However, one critical challenge looms: a shortage of nuclear medicine and radiology physician experts, technologists, and nursing staff capable of delivering this therapy at scale.